Case report shows dual IL‑17A/F blockade produced striking clinical and functional gains within one month in refractory ACH
The February 2026 JDD issue features a case report about a 67‑year‑old man with recalcitrant acrodermatitis continua of Hallopeau (ACH), who is unresponsive to corticosteroids, topical tapinarof, and oral deucravacitinib, and achieved rapid and sustained improvement after starting bimekizumab, an antibody that inhibits both IL‑17A and IL‑17F. Within four weeks the patient had marked clearing of pustular disease and relief of associated joint pain, with continued recovery that allowed return to work. The authors suggest that targeting IL‑17A/F may be particularly effective in neutrophil‑driven, pustular presentations like ACH, but emphasize this is a single‑patient observation.
For the dermatologists, this is a compelling, hypothesis‑generating example: consider dual IL‑17A/F inhibition as an option for refractory ACH after standard therapies fail, discuss risks and insurance considerations with patients, and monitor response and safety closely.
Read the full case for clinical photos, dosing details, and follow‑up; contribute similar cases to the literature or registries to help define which patients may benefit most.
J Drugs Dermatol. 2026;25(2). doi:10.36849/JDD.9417
Blog write-up assisted by AI
